Developing DNA immunotherapies for cancers and infectious diseases

Inovio has developed a powerful technology platform to facilitate the discovery, development and delivery of a new generation of immunotherapies: DNA immunotherapies. These highly optimized synthetic immunotherapies are able to induce strong antibody and T-cell responses. With their novel design of consensus antigens, these immunotherapies may enable our immune system to recognize and eliminate cancerous cells or protect against challenging, changing pathogens. Our R&D efforts are revolutionizing the fight against cancers and infectious diseases and may forever change the course of modern medicine.

With our novel technology platform we have and continue to build a broad pipeline of immunotherapies to fight cancers and infectious diseases that are today untreatable or poorly treated. Inovio is advancing its pipeline of SynCon® immunotherapies both independently and with the support of funding from sponsorships, collaborations, and partnerships. We have ongoing dialog with prospective collaborators and partnerships to provide further development funding and create a commercialization path for promising immune therapy candidates.

Our broad pipeline includes immunotherapies to fight cancers of the cervix, head and neck, prostate, breast, lung, and pancreas as well as to protect against and eliminate infectious diseases such as hepatitis, HIV, Ebola and MERS. We have a robust research and preclinical program that rigorously assesses new immune therapy candidates and has resulted in multiple immunotherapies progressing into clinical studies.